Treatment of prostate and renal cancer with oral drugs (abiratarone and antiangiogenic agents): positioning statement from the Spanish Association of Urology
Actas Urol Esp. 2013 Jun;37(6):321-3.
doi: 10.1016/j.acuro.2013.04.001.
Epub 2013 May 23.
[Article in
English,
Spanish]
Authors
H Villavicencio
1
, C Hernández, A Gómez, J M Cózar, A Rodríguez-Antolín, L Prieto, M de Cabo, J M Malet, J Extramiana, J Mata, M Arrabal, G Server, E Solsona, J I Del Valle, E Miguélez, E Gutiérrez, A Elizalde, J Mateos, J L Artiles, M Jiménez-Cidre, L M Nalda, N Cruz, M Ozonas, J Caffaratti, M Esteban, M Unda, C Reina, J L Alvarez-Ossorio, E Lledó, J C Angulo
Affiliation
- 1 Junta Directiva, Asociación Española de Urología (AEU).
No abstract available
MeSH terms
-
Antineoplastic Agents / administration & dosage*
-
Health Planning Guidelines*
-
Humans
-
Neoplasms / drug therapy*
-
Societies, Medical*